Despite the crucial aid that newly developed target therapies are providing to chemotherapy and stem cell transplant, the cure for many hematological malignancies is still an unmet need. Although available therapies are able to induce an effective debulking of the tumor, most of the time, an insidious minimal residual disease survives current treatments and it is responsible for an immediate or delayed relapse. Peptide-derived antitumor vaccines have been developed with the idea that an artificially "educated" immune system may exert an active specific antitumor response able to control and ultimately eradicate underlying post-treatment residual disease. This review will summarize current knowledge of peptide vaccines for hematological malignancies, trying to analyze promises and pitfalls of a safe and intelligent tool that after many years from its first appearance has not yet established its potential role as alternative immune mediated therapeutic approach for hematopoietic tumors.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Peptide vaccines for hematological malignancies: a missed promise?|
|Citazione:||Bocchia, M., Defina, M., Aprile, L., & Sicuranza, A. (2014). Peptide vaccines for hematological malignancies: a missed promise?. INTERNATIONAL JOURNAL OF HEMATOLOGY, 99(2), 107-116.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: